Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227 - Yahoo Finance

Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227  Yahoo Finance

PRINCETON, N.J.-- -- Study Did Not Meet Its Primary Endpoint of Overall Survival with Opdivo ® Plus Chemotherapy vs. Chemotherapy in First-Line ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more